dapagliflozin
Sponsor AZN · listed as AZN
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
dapagliflozin is a clinical-stage drug asset sponsored by AZN, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jul 2027 (month precision, medium confidence), tied to trial NCT05374291. The asset is in Phase 3 and currently enrolling by invitation, studied in Kidney Disease, Chronic. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2027-07-31
As disclosedJul 2027
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT05374291
PhasePHASE3
StatusENROLLING_BY_INVITATION
Lead sponsorUniversity Medical Center Groningen
Listed asAZN
Condition(s)Kidney Disease, Chronic; Renal Transplant Failure; Heart Failure; Kidney Failure; Death
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More AZN catalysts